HALAVEN

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, Poland, Romania, Singapore, United Kingdom, United States, South Africa

Active ingredients

The drug HALAVEN contains one active pharmaceutical ingredient (API):

1 Eribulin mesylate UNII AV9U0660CW - ERIBULIN MESYLATE

Eribulin is a microtubule dynamics inhibitor belonging to the halichondrin class of antineoplastic agents. It is a structurally simplified synthetic analogue of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai. Read about Eribulin mesylate

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
HALAVEN Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01XX41	Eribulin	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX41

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 10140Q, 10144X, 11199K, 11212D
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 533220020002817, 542714020000002
Country: CA	Health Products and Food Branch	Identifier(s): 02377438
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 5404-MEE-0820
Country: EE	Ravimiamet	Identifier(s): 1523674, 1523685, 1693818, 1693829
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 11678001
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 176930
Country: FR	Base de données publique des médicaments	Identifier(s): 63816522
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 187724
Country: HK	Department of Health Drug Office	Identifier(s): 61632, 65349
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 6835
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291420A1022
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1059639, 1059640, 1078389, 1078390
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 237M2014
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 126713, 98809
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100285229
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W67329001, W67329002
Country: SG	Health Sciences Authority	Identifier(s): 13917P
Country: US	FDA, National Drug Code	Identifier(s): 43624-002, 62856-389
Country: ZA	Health Products Regulatory Authority	Identifier(s): 48/20.2.8/0047